Researchers began a highly anticipated study of two possible Ebola treatments on Thursday in hopes of fighting the still-growing outbreak in eastern Congo, as the World Health Organization announced the enrollment of the first participant.
The virus causing this outbreak, called Bundibugyo, is less common than others that cause Ebola disease and there are no specific treatments or vaccines for it. Already more than 1,400 people have been diagnosed and 438 have died, WHO Director-General Tedros Adhanom Ghebreyesus said Thursday.
Standard supportive care, especially if started early, can help and the WHO says more than 200 people have recovered. But there’s an urgent need for better options.
The trial “offers real hope that we can deliver concrete results for – and with – the communities at the heart of the outbreak,” Tedros said in a statement.
Researchers will be testing if two drugs could improve survival. One is Gilead Sciences’ remdesivir, a broad-acting antiviral approved to treat COVID-19 but that has shown some hints in lab tests that it may help fight the currently spreading virus. The other is Mapp Biopharmaceutical’s experimental MBP134, antibodies engineered to target Ebola viruses including Bundibugyo.
